Bristol-Myers Squibb: Head and Neck Neoplasms trials

The registry lists 10 Head and Neck Neoplasms studies with Bristol-Myers Squibb as lead sponsor. 1 are open to participants now and 1 have results posted.

Phase 1 2Phase 2 5Phase 3 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingNCT03093116Phase 1/2
• Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck CancerCompletedNCT00971867Phase 2Results posted
• A Study of Nivolumab in Patients With Head and Neck Cancer.CompletedNCT04050761
• Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has SpreadCompletedNCT03569436
• Real-World Evidence and Treatment Patterns: Head and Neck CancerCompletedNCT03157674
• Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and CanadaCompletedNCT02705833
• Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck CancerCompletedNCT02110082Phase 1
• Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck CancerCompletedNCT01024101Phase 2
• Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck CancerCompletedNCT00855764Phase 2
• A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck CancerCompletedNCT00337532Phase 2/3